ONCBeOne MedicinesSigning up patients
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 351 (planned)
- Started
- Aug 27, 2025
- Main results expected
- Oct 30, 2027
- Fully finished
- Apr 22, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Model-Predicted Steady State Trough Concentration (Ctrough) of Tislelizumab
Measured over: 85 Days
Model-Predicted Area under the Concentration-time Curve from Time Zero to 21 Days (AUC0-21d) after the First Dose of Tislelizumab
Measured over: 21 Days
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07043400 · record last updated 2026-10-14 · checked 2026-11-09 15:47 UTC